GLP-1 medications activate receptors in key dopamine-rich areas such as the ventral tegmental areas (VTA) and the nucleus accumbens (Nac)
Pharmacotherapy for the management of overweight and obesity
Specifically, between 24 and 72 h post-exercise the repetitions completed were similar that suggests the participants were not sufficiently fatigued at the 24-h time point
About half of all users stop taking GLP-1s within a year and 75% have stopped after two years, likely due to side-effects, such as nausea, and the overall cost involved
Conversely, only 8 source proteins displayed a similar log 2 FC 1.50 and an adjusted p 0.5 transcripts per million (TPM) in at least 20% of samples were selected for further analysis
Those peptides being marketed for longevity or performance have not been rigorously studied in human trials or approved by the FDA, says Kumar